CDEK
← All drugs Report issue

bardoxolone

Small moleculeexperimental

Bardoxolone methyl is an experimental and orally-bioavailable semi-synthetic triterpenoid, based on the scaffold of the natural product oleanolic acid. Pre-clinical studies indicate that the compound acts as an activator of the Nrf2 pathway and an inhibitor of the NF-κB pathway. A phase 3 clinical trial evaluating bardoxolone methyl for the treatment of chronic kidney disease (CKD) was terminated in October 2012 after patients treated with the drug were found to have experienced a higher rate of heart-related adverse events, including heart failure, hospitalizations, and deaths. — Wikipedia

Clinical trial activity

36 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
15
Phase 2
21
Phase 3
9
Phase 4
0

Earliest trial started Apr 1, 2006 (NCT00508807)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC1(C)CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](C(=O)C=C4[C@@]5(C)C=C(C#N)C(=O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]2C1
Mol. weight
491.67 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid methyl ester
  • 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid
  • 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid
  • bardoxolone
  • bardoxolone
  • bardoxolone
  • bardoxolone methyl
  • bardoxolone methyl
  • bardoxolone methyl
  • bardoxolone methyl
  • cddo
  • cddo
  • cddo
  • cddo-me
  • cddo-me
  • cddo-me
  • cddo methyl ester
  • methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate
  • nsc-713200
  • nsc-713200
  • rta-401
  • rta-401
  • rta 402
  • rta 402
  • rta-402
  • rta-402

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04702997Phase 2Feb 9, 2021Reata Pharmaceuticals, Inc.
NCT04494646Phase 2/Phase 3 (Phase 3)Sep 8, 2020New York University, Reata Pharmaceuticals, Inc.
NCT04548427Phase 3Aug 18, 2020Chong Kun Dang Pharmaceutical, Pusan National University
NCT04018339Phase 1Aug 31, 2019Kyowa Hakko Kirin
NCT03918447Phase 3May 29, 2019Reata Pharmaceuticals, Inc.
NCT04023903Phase 1Apr 4, 2019Kyowa Hakko Kirin
NCT03749447Phase 3Mar 8, 2019Reata Pharmaceuticals, Inc.
NCT03550443Phase 3May 30, 2018Kyowa Hakko Kirin
NCT03366337Phase 2Dec 26, 2017Reata Pharmaceuticals, Inc.
NCT03264079Phase 1Oct 16, 2017Reata Pharmaceuticals, Inc.
NCT03068130Phase 3Apr 18, 2017Reata Pharmaceuticals, Inc.
NCT03019185Phase 2/Phase 3 (Phase 3)Mar 2, 2017Reata Pharmaceuticals, Inc.
NCT02657356Phase 3Sep 1, 2016Reata Pharmaceuticals, Inc.
NCT02316821Phase 2Dec 1, 2014Kyowa Hakko Kirin
NCT02036970Phase 2May 1, 2014Reata Pharmaceuticals, Inc.
NCT01655186Phase 2Sep 1, 2012Reata Pharmaceuticals, Inc.
NCT01689116Phase 1Aug 1, 2012Reata Pharmaceuticals, Inc.
NCT01576887Phase 2Jul 1, 2012Reata Pharmaceuticals, Inc.
NCT01549769Phase 1Apr 1, 2012Reata Pharmaceuticals, Inc.
NCT01563562Phase 1Apr 1, 2012Reata Pharmaceuticals, Inc.
Showing 20 of 36 trials
Page 1 / 2

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Reata Pharmaceuticals, Inc.For profit282632006
Kyowa Hakko KirinFor profit6632012
Chong Kun Dang PharmaceuticalFor profit1112020
CovanceFor profit1012011
National Cancer Institute (NCI)Government1112006
New York UniversityAcademic/Hospital1112020
Orlando Clinical Research CenterFor profit1012007
Pusan National UniversityAcademic/Hospital1012020
University of Texas at HoustonAcademic/Hospital1112006
9 organizations
Page 1 / 1